Quidel, a developer of diagnostic solutions for infectious diseases, has received CE mark approval for its Molecular Influenza A+B real-time RT-PCR assay.
The Influenza A+B test detects and differentiates influenza type A and type B antigens directly from nasal swab, nasopharyngeal swab, nasal wash and/or nasal aspirate specimens.
The results are obtained with in 10 minutes or less.
The assays offers benefits like room temperature storage, reduced process time and reagent configurations.
Quidel’s diagnostic products also aid in the detection and diagnosis of other infectious diseases like respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood.